DEA, HHC, and Synthetic Cannabinoids: Federal Legal Status Explained

Executive Summary

The Drug Enforcement Administration is defending its position that hexahydrocannabinol (HHC) and related synthetic cannabinoids fall under federal prohibition under the Controlled Substances Act, despite industry legal challenges arguing these compounds derive from legal hemp. The DEA's stance, articulated in court filings responding to multiple industry lawsuits filed in 2025 and 2026, maintains that HHC qualifies as a Schedule I controlled substance because its chemical synthesis process creates a tetrahydrocannabinol analog not explicitly exempted by the 2018 Farm Bill. This regulatory position threatens a multi-hundred-million-dollar segment of the hemp-derived cannabinoid market that emerged after 2020, affecting manufacturers, retailers, and consumers across states where these products have been sold legally under state hemp programs. The legal battle centers on competing interpretations of the Controlled Substances Act's definition of "tetrahydrocannabinols" under 21 U.S.C. § 812 and whether the Agriculture Improvement Act of 2018 created an exception for hemp-derived compounds regardless of synthesis method. Industry plaintiffs argue the DEA is exceeding its statutory authority by effectively rewriting the Farm Bill's hemp definition, while the agency contends it is applying longstanding chemical scheduling principles to synthetic analogs that Congress never intended to legalize.

Why This Matters

The DEA's interpretation of HHC's legal status will determine whether hundreds of hemp businesses can continue operating and whether millions of consumers retain access to products marketed as legal alternatives to traditional cannabis. The stakes extend across multiple stakeholder groups. For the hemp industry, an estimated $500 million to $800 million in annual HHC product sales hangs in the balance, according to hemp industry trade groups. Manufacturers who invested in extraction and synthesis equipment, retailers who stocked these products, and distributors who built supply chains all face potential criminal liability if the DEA's position prevails in court. For consumers, particularly in states without adult-use cannabis programs, HHC and similar compounds have provided legal access to psychoactive cannabinoids. An estimated 15 to 20 million Americans have purchased HHC products since 2021, according to market research firms tracking the hemp-derived cannabinoid sector. State regulators face enforcement dilemmas. Many states have permitted HHC sales under their hemp programs, creating a conflict between state-legal commerce and federal prohibition claims. States including Texas, Georgia, and Florida have seen robust HHC markets develop, while others like Colorado and Oregon have moved to restrict these products under state cannabis regulations. The legal precedent matters beyond HHC. The court's interpretation of how the Farm Bill interacts with the Controlled Substances Act will affect the regulatory status of delta-8 THC, THC-O, delta-10 THC, and other semi-synthetic cannabinoids that have proliferated in the hemp market. The outcome will either validate or constrain the DEA's authority to classify hemp-derived compounds as controlled substances based on synthesis methodology rather than source material. Federal prosecutors and law enforcement agencies are watching closely. If courts uphold the DEA's authority to classify HHC as Schedule I, it provides a legal framework for enforcement actions against what has been a largely unregulated market segment. Conversely, an industry victory would limit the DEA's ability to restrict hemp-derived compounds without explicit Congressional action.

Background and History

The HHC controversy emerged from the intersection of the 2018 Farm Bill's hemp legalization, advances in cannabinoid chemistry, and the DEA's traditional approach to scheduling synthetic analogs of controlled substances.

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act. The law defined hemp as Cannabis sativa L. and any part of that plant, including all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis. This definition appeared to legalize all compounds derived from hemp plants meeting the THC threshold, but it left ambiguous whether chemically modified or synthesized cannabinoids retained their hemp-derived legal status. The law directed the U.S. Department of Agriculture to establish regulations for hemp production, which the USDA published as an interim final rule in October 2019 and finalized in January 2021. The DEA published an interim final rule in August 2020 implementing the statutory changes, stating that "synthetically derived tetrahydrocannabinols remain Schedule I controlled substances" even if the synthesis process begins with hemp-derived material. This language planted the seeds for future conflicts over compounds like HHC.

Discovery and Early Development of HHC

Hexahydrocannabinol is not a new compound. Chemist Roger Adams first synthesized HHC in 1944 by adding hydrogen molecules to delta-9 THC extracted from cannabis, a process called hydrogenation. The compound remained largely a laboratory curiosity for decades, with limited research into its pharmacological properties. HHC exists naturally in cannabis plants, but only in trace amounts insufficient for commercial extraction. The compound consists of multiple stereoisomers, with 9R-HHC generally considered more psychoactive than 9S-HHC. The hydrogenation process that converts THC to HHC adds hydrogen atoms to the double bond in THC's molecular structure, creating a more stable compound less susceptible to oxidation and degradation.

The Delta-8 THC Market Precedent (2020-2021)

Before HHC gained commercial traction, delta-8 THC established the template for hemp-derived intoxicating cannabinoid products. Following the 2018 Farm Bill, manufacturers discovered they could convert CBD extracted from legal hemp into delta-8 THC through chemical processes involving acids and heat. Delta-8 THC products exploded across the market in 2020 and 2021, sold in gas stations, smoke shops, and online retailers. The DEA and FDA issued warnings but took limited enforcement action, creating a perception that hemp-derived cannabinoids occupied a legal gray zone. Some states moved to explicitly ban delta-8 THC, while others allowed sales to continue under hemp programs. The delta-8 market demonstrated consumer demand for legal psychoactive cannabinoids and showed manufacturers that chemical conversion of hemp-derived CBD could create profitable product lines. It also revealed regulatory gaps and enforcement challenges that would later apply to HHC.

HHC Market Emergence (2021-2023)

HHC products began appearing in the hemp market in late 2021 and gained significant market share throughout 2022 and 2023. Manufacturers marketed HHC as a legal alternative to delta-9 THC with purported advantages: greater stability, longer shelf life, and effects similar to traditional THC. The production process typically starts with CBD extracted from legal hemp. Through chemical processes involving hydrogenation catalysts, manufacturers convert CBD to HHC. The resulting product is then formulated into vapes, edibles, tinctures, and other consumer products similar to those in regulated cannabis markets. By 2023, HHC products were available in thousands of retail locations across the United States, particularly in states without adult-use cannabis programs. Online retailers shipped HHC products across state lines, treating them as legal hemp derivatives. The market operated with minimal federal oversight and inconsistent state regulation.

DEA Interim Final Rule and Industry Response (2023-2024)

In February 2023, the DEA published guidance clarifying that it considered HHC and similar compounds to be controlled substances when synthetically derived, regardless of the source material. The agency stated that the Farm Bill's hemp exception did not extend to cannabinoids created through chemical synthesis, even if the starting material was legal hemp-derived CBD. Industry groups responded that the DEA was misinterpreting the Farm Bill and exceeding its statutory authority. They argued that the law's definition of hemp explicitly included "all derivatives" and "all isomers" of hemp-derived material, which should encompass chemically converted compounds like HHC. The U.S. Hemp Roundtable, the Hemp Industries Association, and individual companies began preparing legal challenges. They contended that if a compound derives from legal hemp and contains less than 0.3 percent delta-9 THC, it falls under the Farm Bill's hemp definition regardless of synthesis steps. Throughout 2023 and 2024, the DEA did not launch widespread enforcement actions against HHC manufacturers, but the regulatory uncertainty chilled investment and complicated state-level regulation. Some manufacturers reformulated products or exited the HHC market, while others continued operations while preparing for potential legal battles.

Industry Lawsuits Filed (2025-2026)

Multiple hemp industry plaintiffs filed federal lawsuits in 2025 challenging the DEA's authority to classify HHC as a controlled substance. Cases were filed in the U.S. District Court for the District of Columbia, the Northern District of California, and other jurisdictions, seeking declaratory judgments that HHC derived from hemp falls under the Farm Bill's hemp exception. The lawsuits argued that the DEA's interpretation violated the Administrative Procedure Act by effectively amending the Farm Bill without Congressional authorization. Plaintiffs contended that the Controlled Substances Act's scheduling authority does not extend to substances Congress explicitly removed from Schedule I through the 2018 Farm Bill. In June 2026, the DEA filed formal responses defending its position. The agency's court filings argued that the Controlled Substances Act's definition of "tetrahydrocannabinols" in 21 U.S.C. § 812, Schedule I(c)(17) encompasses synthetic analogs and that the Farm Bill did not create an unlimited exception for any compound derived through any process from hemp starting material.

Key Players

Drug Enforcement Administration

The DEA, operating under the Department of Justice, maintains authority to schedule controlled substances under the Controlled Substances Act. The agency's Diversion Control Division oversees implementation of the Act's requirements for controlled substance manufacturers, distributors, and dispensers. Administrator Anne Milgram has overseen the agency's cannabis policy during this period, though day-to-day scheduling decisions are handled by career officials in the Office of Diversion Control. The DEA's position on HHC reflects the agency's traditional approach to synthetic cannabinoids, which it has consistently treated as Schedule I substances since the emergence of compounds like JWH-018 and other synthetic cannabinoid receptor agonists in the 2000s.

Hemp Industry Association

The Hemp Industries Association, founded in 1994, represents hemp farmers, processors, manufacturers, and retailers. The organization has been a leading voice challenging the DEA's interpretation of the Farm Bill's hemp definition. The association argues that overly restrictive interpretations of hemp-derived compounds threaten the economic viability of the hemp industry that Congress intended to support through the 2018 Farm Bill.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable is a coalition of hemp businesses and stakeholders that advocated for the 2018 Farm Bill's hemp provisions. The organization has filed amicus briefs in HHC litigation supporting industry plaintiffs and has lobbied Congress for clarifying legislation that would explicitly protect hemp-derived cannabinoids from DEA scheduling authority.

Individual Manufacturer Plaintiffs

Several hemp product manufacturers have filed lawsuits as named plaintiffs, including companies that invested substantial capital in HHC production equipment and product development. These companies face potential criminal liability if the DEA's position prevails, making them directly injured parties with standing to challenge the agency's interpretation.

Food and Drug Administration

The FDA has regulatory authority over food, dietary supplements, and drugs, creating overlapping jurisdiction with the DEA on cannabinoid products. The agency has issued warning letters to companies marketing HHC products with therapeutic claims but has not taken a definitive position on whether HHC qualifies as a legal hemp derivative. The FDA's Center for Drug Evaluation and Research and Center for Food Safety and Applied Nutrition both have roles in cannabinoid regulation.

State Regulators

State departments of agriculture and cannabis control agencies have taken varied approaches to HHC. States including Michigan, Colorado, and Oregon have moved to restrict HHC under state cannabis laws, while states like Texas and Florida have permitted sales under hemp programs. This patchwork creates compliance challenges for multi-state operators and online retailers.

Congressional Hemp Caucus

Members of Congress who supported the 2018 Farm Bill, including representatives from major hemp-producing states like Kentucky, North Carolina, and Oregon, have expressed concern that the DEA's interpretation undermines Congressional intent. Some members have introduced legislation to clarify that all hemp-derived compounds fall under the Farm Bill's exception, though no such bills have advanced to passage as of June 2026.

Legal and Regulatory Framework

The legal dispute over HHC turns on the interaction between the Controlled Substances Act's scheduling provisions and the 2018 Farm Bill's hemp exception, with both sides claiming statutory authority for their positions.

Controlled Substances Act Scheduling of THC

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Schedule I, the most restrictive category, includes substances with high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. Under 21 U.S.C. § 812, Schedule I(c)(17), "tetrahydrocannabinols" are listed as Schedule I controlled substances. The statute does not define this term with chemical precision, leading to disputes over which specific compounds fall within the category. The DEA has historically interpreted this provision broadly to include THC isomers and synthetic analogs. The Act grants the Attorney General, who has delegated authority to the DEA Administrator, power to add substances to schedules or transfer substances between schedules through rulemaking under 21 U.S.C. § 811. This process requires findings regarding abuse potential, scientific evidence, and other factors specified in the statute.

The 2018 Farm Bill Hemp Definition

The Agriculture Improvement Act of 2018, Public Law 115-334, amended the Controlled Substances Act to exclude hemp from the definition of marijuana. Section 10113 of the Farm Bill added a definition of hemp to 7 U.S.C. § 1639o as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The law's use of "any part" and "all derivatives" appears comprehensive, but it does not explicitly address whether chemical synthesis processes that alter molecular structure preserve hemp-derived legal status. The statute's legislative history shows Congressional intent to support hemp agriculture and remove regulatory barriers, but does not directly discuss synthetic cannabinoids. Section 12619 of the Farm Bill amended 21 U.S.C. § 802(16) to exclude hemp from the Controlled Substances Act's definition of marijuana, creating the legal foundation for hemp commerce. However, this exclusion operates within the existing framework of the Controlled Substances Act's scheduling of specific cannabinoids.

DEA Interim Final Rule (2020)

The DEA's August 21, 2020 interim final rule, published at 85 Fed. Reg. 51639, implemented the Farm Bill's changes. The rule stated: "For synthetically derived tetrahydrocannabinols, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance. All synthetically derived tetrahydrocannabinols remain schedule I controlled substances." This language established the DEA's position that the method of production, not just the source material or final delta-9 THC concentration, determines controlled substance status. The agency defined "synthetically derived" to include cannabinoids produced through chemical synthesis, chemical modification, or chemical conversion, even if starting from hemp-derived precursors. Industry commenters objected during the rulemaking process, arguing this interpretation contradicted the Farm Bill's plain language. The DEA responded that Congress did not intend to legalize synthetic cannabinoids and that the agency retained authority to regulate synthetically derived compounds under the Controlled Substances Act.

Administrative Procedure Act Standards

The industry lawsuits challenging the DEA's HHC position invoke the Administrative Procedure Act, codified at 5 U.S.C. § 551 et seq. Under 5 U.S.C. § 706, courts must set aside agency action that is "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law" or "in excess of statutory jurisdiction, authority, or limitations." Plaintiffs argue the DEA's interpretation exceeds its statutory authority because Congress explicitly removed hemp and all hemp derivatives from Schedule I through the Farm Bill. They contend the agency cannot reinstate scheduling through regulatory interpretation of the term "synthetically derived." The DEA counters that its interpretation is entitled to deference under Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984), because the Farm Bill is ambiguous regarding synthetic derivatives and the agency's interpretation is reasonable. However, recent Supreme Court decisions have narrowed Chevron deference, potentially affecting this analysis.

Analog Act Implications

The Controlled Substances Analogue Enforcement Act of 1986, codified at 21 U.S.C. § 813, provides that a substance substantially similar to a Schedule I or II controlled substance is treated as a Schedule I substance if intended for human consumption. The DEA has cited this provision in enforcement actions against synthetic cannabinoids. The Analog Act defines a controlled substance analog as a substance with a chemical structure substantially similar to a Schedule I or II substance, or with a stimulant, depressant, or hallucinogenic effect substantially similar to or greater than a Schedule I or II substance. HHC's structural similarity to delta-9 THC potentially brings it within this definition. However, the Analog Act contains an exception for substances "not intended for human consumption," which some manufacturers have attempted to invoke through labeling disclaimers. Courts have generally rejected such disclaimers as pretextual when products are clearly marketed for consumption.

State-by-State Breakdown

States have adopted widely varying approaches to HHC and synthetic cannabinoids, creating a complex patchwork of legal status that complicates interstate commerce and consumer access.

States Permitting HHC Under Hemp Programs

Texas has allowed HHC sales under its hemp program administered by the Texas Department of State Health Services. The state's hemp law, enacted following the 2018 Farm Bill, does not explicitly address synthetic cannabinoids. HHC products are available in retail stores throughout the state, with no possession limits beyond those applicable to hemp generally. Texas has not moved to restrict HHC despite the DEA's position. Florida permits HHC sales under its hemp regulations established by the Florida Department of Agriculture and Consumer Services. The state's hemp program focuses on delta-9 THC concentration testing and does not prohibit hemp-derived synthetic cannabinoids. Florida's large hemp market has seen substantial HHC product availability since 2022. Georgia allows HHC under its hemp farming program. The Georgia Department of Agriculture has not issued guidance restricting synthetic hemp-derived cannabinoids. Possession limits align with general hemp provisions, with no specific quantity restrictions on HHC products. North Carolina, a major hemp-producing state, has permitted HHC sales under its hemp program. The North Carolina Department of Agriculture and Consumer Services has not adopted restrictions on hemp-derived cannabinoids beyond delta-9 THC concentration limits. The state's hemp industry has advocated for maintaining broad hemp derivative legality.

States Restricting or Banning HHC

Colorado has moved to regulate HHC under its cannabis control framework rather than hemp law. The Colorado Marijuana Enforcement Division issued guidance in 2023 stating that intoxicating hemp-derived cannabinoids, including HHC, must be sold through licensed cannabis retailers and comply with cannabis testing and packaging requirements. This effectively restricts HHC to the regulated cannabis market. Oregon has taken a similar approach, with the Oregon Liquor and Cannabis Commission asserting jurisdiction over HHC products. The state requires that any intoxicating cannabinoid product, regardless of source, be sold through licensed cannabis retailers. Possession limits align with Oregon's cannabis possession laws: up to two ounces in public, eight ounces at home. Michigan amended its hemp law in 2024 to explicitly prohibit synthetic cannabinoids including HHC. The Michigan Department of Agriculture and Rural Development now restricts hemp products to naturally occurring cannabinoids without chemical conversion. The state's Cannabis Regulatory Agency has jurisdiction over any intoxicating cannabinoid products. New York has prohibited HHC sales outside its licensed cannabis market. The New York Office of Cannabis Management issued guidance in 2023 stating that hemp-derived intoxicating cannabinoids require licensure under the state's cannabis law. Unlicensed HHC sales are subject to enforcement action.

States With Ambiguous or Evolving Positions

California has not issued definitive guidance on HHC's status under its hemp or cannabis regulations. The California Department of Food and Agriculture oversees hemp, while the Department of Cannabis Control regulates cannabis. This jurisdictional split has created uncertainty, with some retailers selling HHC as hemp and others avoiding the product due to legal ambiguity. Illinois has seen HHC products in the market but has not clarified whether they fall under hemp or cannabis jurisdiction. The Illinois Department of Agriculture administers the hemp program, while the Department of Financial and Professional Regulation oversees cannabis. Industry stakeholders have requested clarification without receiving definitive guidance. Ohio is in transition following recent adult-use cannabis legalization. The state's hemp program previously allowed HHC sales, but the Division of Cannabis Control is developing regulations that may bring intoxicating hemp-derived cannabinoids under cannabis jurisdiction. The regulatory framework remains in flux as of June 2026.

Market and Business Implications

The DEA's position on HHC threatens to eliminate a significant market segment while raising fundamental questions about the viability of hemp-derived cannabinoid innovation.

Market Size and Revenue Impact

Industry analysts estimate the HHC market generated between $500 million and $800 million in retail sales in 2025. This represents approximately 5 to 8 percent of the total hemp-derived cannabinoid market, which includes CBD, delta-8 THC, and other compounds. The market grew rapidly from 2022 through 2024 before plateauing amid regulatory uncertainty. If the DEA's position prevails in court, manufacturers face potential product seizures, criminal liability, and civil penalties. Retailers holding HHC inventory would need to dispose of products or risk prosecution. The ripple effects would extend to equipment manufacturers, testing laboratories, and ancillary service providers who built businesses around the HHC market.

Investment and Capital Markets

The regulatory uncertainty has already chilled investment in hemp-derived cannabinoid companies. Venture capital and private equity firms have reduced funding for businesses focused on semi-synthetic cannabinoids, preferring investments in traditional CBD products or state-licensed cannabis operators. Public hemp companies have seen stock prices decline on news of DEA enforcement positions. Companies that disclosed significant HHC revenue in securities filings have faced investor lawsuits alleging inadequate risk disclosure. The capital markets impact extends beyond HHC-focused businesses to the broader hemp sector, as investors question the regulatory stability of any hemp-derived cannabinoid beyond CBD.

Multi-State Operator Strategic Decisions

Cannabis multi-state operators (MSOs) that also operate hemp businesses face strategic decisions about HHC. Some MSOs have exited the hemp-derived cannabinoid market entirely to avoid jeopardizing their state cannabis licenses. Others have maintained separate corporate structures to isolate legal risk. Licensed cannabis operators generally view HHC and similar products as competition that undercuts regulated markets. These products are sold without the testing, packaging, and taxation requirements that apply to state-licensed cannabis, creating price advantages that licensed operators argue constitute unfair competition. Some MSOs have lobbied state regulators to restrict hemp-derived intoxicating cannabinoids.

Testing Laboratory and Compliance Challenges

Testing laboratories face technical and legal challenges with HHC. Analytical methods for detecting and quantifying HHC are less standardized than those for delta-9 THC and CBD. Laboratories must distinguish between HHC stereoisomers and identify potential contaminants from synthesis processes. If HHC is definitively classified as Schedule I, laboratories testing HHC products may need DEA registration as analytical laboratories handling controlled substances. This would impose additional regulatory burdens and costs. Some laboratories have stopped accepting HHC samples to avoid potential legal exposure.

Insurance and Banking Access

Hemp businesses selling HHC have faced increasing difficulty obtaining business insurance and banking services. Insurance carriers have excluded coverage for synthetic cannabinoid products or charged substantially higher premiums. Banks have closed accounts for hemp businesses with HHC revenue, citing concerns about federal money laundering statutes and the Bank Secrecy Act. The financial services challenges mirror those faced by state-licensed cannabis businesses, despite hemp's ostensibly legal status under the Farm Bill. Payment processors have similarly restricted hemp businesses selling HHC, forcing many to operate on cash-only basis or use high-risk payment processing services with elevated fees.

What Experts Say

Legal scholars, industry consultants, and policy advocates have offered competing analyses of the DEA's authority and the likely outcome of litigation over HHC's status. Cannabis law attorneys representing industry plaintiffs have argued that the DEA is impermissibly rewriting the Farm Bill through regulatory interpretation. According to attorneys at Vicente Sederberg LLP, a national cannabis law firm, the Farm Bill's language "all derivatives" and "all isomers" is unambiguous and encompasses compounds derived from hemp through any process, including chemical synthesis. They contend that if Congress intended to exclude synthetic derivatives, it would have included limiting language in the statute. Administrative law professors have noted that the case presents questions about agency deference and statutory interpretation that align with recent Supreme Court trends limiting Chevron deference. According to analysis from the Drug Enforcement and Policy Center at Ohio State University, courts may apply a less deferential standard of review to the DEA's interpretation, particularly given that the Farm Bill represents a clear Congressional policy choice to legalize hemp. Hemp industry consultants have emphasized the practical impossibility of distinguishing "natural" from "synthetic" cannabinoids in many cases. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has stated in public comments that virtually all hemp-derived cannabinoid products undergo some chemical processing, making the DEA's synthetic/natural distinction unworkable as a regulatory framework. Toxicologists and pharmacologists have raised concerns about HHC product safety regardless of legal status. According to researchers at the University of Mississippi's National Center for Natural Products Research, HHC products often contain impurities from synthesis processes and lack standardized dosing, creating public health risks. These experts have called for regulatory oversight of hemp-derived intoxicating cannabinoids whether classified as hemp or controlled substances. Former DEA officials have defended the agency's position. According to statements from former DEA administrators, the Controlled Substances Act's scheduling authority extends to analogs and synthetic compounds to prevent circumvention of drug laws through minor chemical modifications. They argue that allowing unlimited chemical derivation from hemp would create a loophole undermining the entire controlled substances framework. State cannabis regulators have generally supported bringing intoxicating hemp-derived cannabinoids under cannabis regulatory frameworks. According to the Cannabis Regulators Association, a national organization of state cannabis regulators, products with intoxicating effects should be subject to testing, labeling, and distribution controls regardless of source material. These regulators have expressed frustration that hemp-derived products compete with regulated cannabis without equivalent consumer protections. Public health advocates have called for Congressional action to clarify the regulatory framework. According to policy positions from the Network for Public Health Law, the current ambiguity serves neither public health nor industry interests, and Congress should explicitly define which hemp-derived compounds are legal and what regulatory standards apply.

What's Next

The legal and regulatory trajectory for HHC will unfold through federal court decisions, potential Congressional action, and state-level regulatory developments over the next 12 to 24 months. The federal court cases challenging the DEA's HHC position are in early stages as of June 2026. District court decisions on motions to dismiss or for summary judgment are expected in late 2026 or early 2027. Whichever side loses at the district court level will likely appeal, meaning definitive resolution could take two to three years to reach the circuit court level. If the cases produce conflicting decisions across different circuit courts, the Supreme Court could eventually take up the issue to resolve the circuit split. However, Supreme Court review is not guaranteed and would add additional years to the timeline. In the interim, the regulatory status of HHC will remain uncertain, with enforcement varying by jurisdiction. Congress could intervene to clarify the Farm Bill's scope before litigation concludes. Several bills have been introduced to explicitly protect hemp-derived cannabinoids from DEA scheduling, but none have advanced through committee as of June 2026. The hemp industry is lobbying for inclusion of clarifying language in the next Farm Bill reauthorization, expected in 2028 or 2029. The DEA could initiate formal rulemaking to schedule HHC explicitly as a Schedule I substance under 21 U.S.C. § 811. This would require notice-and-comment rulemaking and findings regarding abuse potential, medical use, and other statutory factors. Such a process would take at least 12 to 18 months and would be subject to separate legal challenges, but would provide more definitive regulatory status than the current interpretive approach. State legislatures are likely to continue addressing HHC and similar compounds through state law. States may move to explicitly prohibit these products, regulate them under cannabis frameworks, or maintain hemp program permissiveness. The trend appears to be toward greater state-level restriction, particularly in states with established cannabis markets where hemp-derived intoxicating cannabinoids are viewed as competition. The FDA may assert more active jurisdiction over HHC products. The agency has authority to regulate food, dietary supplements, and drugs, and could issue enforcement guidance or warning letters targeting HHC manufacturers. The FDA has been developing a regulatory framework for CBD products and could extend that framework to other hemp-derived cannabinoids. Industry consolidation is likely regardless of legal outcomes. Smaller manufacturers and retailers may exit the HHC market due to legal uncertainty and compliance costs, while larger operators with more resources may continue operations or pivot to other product lines. The market may shift toward less legally ambiguous cannabinoids or toward state-licensed cannabis channels. Key dates to watch include scheduled court hearings in the pending federal cases, the DEA's semiannual regulatory agenda publications indicating potential rulemaking, and state legislative sessions in 2027 where hemp and cannabis bills will be considered. The hemp industry's annual conferences and trade shows will provide forums for stakeholder coordination and strategy development.

Further Reading

• Agriculture Improvement Act of 2018 (2018 Farm Bill), Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• Controlled Substances Act, 21 U.S.C. § 801 et seq., full text at https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• DEA Interim Final Rule: Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639 (August 21, 2020), available at https://www.federalregister.gov/documents/2020/08/21/2020-18455/implementation-of-the-agriculture-improvement-act-of-2018
• U.S. Hemp Roundtable resources and policy positions at https://www.hempsupporter.com
• Hemp Industries Association legal updates at https://www.thehia.org
• USDA Hemp Production Program regulations at https://www.ams.usda.gov/rules-regulations/hemp
• FDA Cannabis and Cannabis-Derived Compounds information page at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• National Conference of State Legislatures state hemp and CBD laws database at https://www.ncsl.org/health/state-medical-cannabis-laws
• Congressional Research Service reports on hemp and cannabis law at https://crsreports.congress.gov
• Drug Enforcement and Policy Center at Ohio State University research and analysis at https://drugpolicy.osu.edu